Inflammatory and Angiogenic Mediators in Amniotic Fluid Are Associated With the Development of Retinopathy of Prematurity in Preterm Infants.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
11 05 2020
Historique:
entrez: 24 5 2020
pubmed: 24 5 2020
medline: 29 9 2020
Statut: ppublish

Résumé

To investigate whether elevated levels of inflammatory/angiogenic and growth mediators in amniotic fluid (AF) and the presence of intra-amniotic infection are associated with the occurrence and progression of retinopathy of prematurity (ROP) in preterm infants. This retrospective cohort study included 175 premature singleton infants who were born between 23+0 and 32+0 weeks. AF obtained via amniocentesis was cultured, and endoglin, endostatin, insulin-like growth factor-binding protein (IGFBP)-2, IGFBP-3, IGFBP-4, IL-6, IL-8, matrix metalloproteinase-8, matrix metalloproteinase-9, and vascular endothelial growth factor receptor-1 levels were assayed by ELISA. The primary outcome measures included the occurrence of any stage ROP, severe ROP (stage ≥3), and vision-threatening type 1 ROP requiring treatment. Multiple logistic regression analyses revealed that there are significant associations between elevated AF endoglin levels and ROP occurrence; between elevated AF endoglin, endostatin, and IGFBP-2 levels and severe ROP; and between high AF endoglin, IL-6, and IL-8 levels and vision-threatening ROP requiring treatment, after adjusting for potential postnatal confounders. Using stepwise regression analyses, antenatal prediction models based on these AF biomarkers and prenatal factors were developed for the ROP outcomes, which had good discriminatory power (area under the curves, 0.731-0.863). However, we found that intra-amniotic infection is not associated with ROP occurrence and progression. Elevated levels of inflammatory (IL-6 and IL-8) and angiogenic (endoglin and IGFBP-2) mediators in the AF, but not the presence of intra-amniotic infection, are independently associated with the occurrence and progression of ROP in preterm infants. These findings suggest that the pathophysiologic events that predispose preterm neonates to ROP may begin before delivery.

Identifiants

pubmed: 32446247
pii: 2766241
doi: 10.1167/iovs.61.5.42
pmc: PMC7405804
doi:

Substances chimiques

Angiogenesis Inducing Agents 0
Angiogenic Proteins 0
Biomarkers 0
Inflammation Mediators 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

42

Références

Curr Eye Res. 2015 Mar;40(3):321-31
pubmed: 24871583
Acta Obstet Gynecol Scand. 2013 May;92(5):517-24
pubmed: 23324124
Anticancer Res. 2011 Jun;31(6):2283-90
pubmed: 21737653
Gynecol Obstet Invest. 2006;61(1):40-4
pubmed: 16179789
Retina. 2013 Oct;33(9):1809-14
pubmed: 23492946
Pediatr Res. 2017 Feb;81(2):349-355
pubmed: 27925622
Arch Ophthalmol. 2003 Dec;121(12):1684-94
pubmed: 14662586
Acta Obstet Gynecol Scand. 2018 Apr;97(4):400-406
pubmed: 29341101
Mediators Inflamm. 2018 Sep 19;2018:4209359
pubmed: 30327582
Pediatr Nephrol. 2000 Jul;14(7):572-8
pubmed: 10912521
J Neuroinflammation. 2017 Aug 22;14(1):165
pubmed: 28830469
Invest Ophthalmol Vis Sci. 2011 Sep 01;52(10):7052-8
pubmed: 21775664
Pediatrics. 2013 Jan;131(1):189-95
pubmed: 23277315
Angiogenesis. 2017 Feb;20(1):1-24
pubmed: 27943030
Pediatr Res. 2010 Apr;67(4):394-400
pubmed: 20032809
J Infect Dis. 1982 Jan;145(1):1-8
pubmed: 7033397
Am J Reprod Immunol. 2013 Feb;69(2):105-23
pubmed: 23279628
BJOG. 2003 Apr;110 Suppl 20:124-7
pubmed: 12763129
Ophthalmology. 2015 Jan;122(1):200-10
pubmed: 25444347
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):5076-5082
pubmed: 27679852
Nat Med. 2006 Jun;12(6):642-9
pubmed: 16751767
Semin Reprod Med. 2007 Jan;25(1):21-39
pubmed: 17205421
Dis Model Mech. 2018 Sep 21;11(9):
pubmed: 30108051
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6419-6428
pubmed: 29260199
J Korean Med Sci. 2013 Aug;28(8):1226-32
pubmed: 23960452
N Engl J Med. 2012 Dec 27;367(26):2515-26
pubmed: 23268666
Invest Ophthalmol Vis Sci. 2011 Mar 10;52(3):1297-301
pubmed: 21071735
Reprod Sci. 2012 Jun;19(6):658-65
pubmed: 22457430
Invest Ophthalmol Vis Sci. 2013 May 15;54(5):3434-9
pubmed: 23633656
Curr Opin Obstet Gynecol. 2000 Jun;12(3):163-8
pubmed: 10873115
Arch Ophthalmol. 2010 Jun;128(6):663-71
pubmed: 20385926
Acta Paediatr. 2010 Apr;99(4):519-25
pubmed: 20085549
Pediatrics. 2006 Feb;117(2):572-6
pubmed: 16452383
Am J Obstet Gynecol. 2017 Sep;217(3):354.e1-354.e8
pubmed: 28545834
Arch Ophthalmol. 2002 Aug;120(8):1075-80
pubmed: 12149062
Lancet. 2013 Oct 26;382(9902):1445-57
pubmed: 23782686
Lancet. 2012 Feb 4;379(9814):445-52
pubmed: 22244654
Semin Fetal Neonatal Med. 2012 Feb;17(1):26-9
pubmed: 21903492
Pediatr Res. 2013 Dec;74 Suppl 1:35-49
pubmed: 24366462
Pediatr Res. 2005 Apr;57(4):605-10
pubmed: 15695599
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5312-5319
pubmed: 30398622
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3813-3820
pubmed: 31525777
Pediatrics. 2011 Mar;127(3):e607-14
pubmed: 21321036
Ophthalmology. 2016 Apr;123(4):804-16
pubmed: 26832657
Exp Cell Res. 2006 Mar 10;312(5):594-607
pubmed: 16376330
Surv Ophthalmol. 2018 Sep - Oct;63(5):618-637
pubmed: 29679617
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Growth Horm IGF Res. 2018 Apr;39:19-24
pubmed: 29274846

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH